Welcome to the Schizophrenia Resource Centre

Welcome, this website is intended for healthcare professionals in EMEA with an interest in the treatment of schizophrenia. By clicking the link below you are declaring and confirming that you are a healthcare professional

You are here

Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study.

Alphs L, Benson C, Cheshire-Kinney K, Lindenmayer JP, Mao L, Rodriguez SC, Starr HL.

J Clin Psychiatry. 2015 May;76(5):554-61. doi: 10.4088/JCP.14m09584.

Abstract

OBJECTIVE:

The Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study compared the effects of once-monthly paliperidone palmitate with daily oral antipsychotics on treatment failure in adults with schizophrenia.

METHOD:

The PRIDE study is a 15-month, randomized, multicenter study (May 5, 2010, to December 9, 2013) of adult subjects with a DSM-IV diagnosis of schizophrenia and a history of incarceration. Subjects were randomly assigned to once-monthly paliperidone palmitate injections or daily oral antipsychotics (randomly assigned from 7 acceptable, prespecified oral antipsychotics) for 15 months. The primary end point was time to first treatment failure, defined as arrest/incarceration; psychiatric hospitalization; suicide; treatment discontinuation or supplementation due to inadequate efficacy, safety, or tolerability; or increased psychiatric services to prevent hospitalization. Time to first treatment failure was determined by a blinded event-monitoring board and analyzed with the Kaplan-Meier method.

RESULTS:

In this study, 450 patients were randomly assigned, and 444 were included in the intent-to-treat population. Paliperidone palmitate was associated with significant delay in time to first treatment failure versus oral antipsychotics (hazard ratio, 1.43; 95% CI, 1.09-1.88; log rank P = .011). Observed treatment failure rates over 15 months were 39.8% and 53.7%, respectively. Arrest/incarceration and psychiatric hospitalization were the most common reasons for treatment failure in the paliperidone palmitate and oral antipsychotic groups (21.2% vs 29.4% and 8.0% vs 11.9%, respectively). The 5 most common treatment-emergent adverse events for the paliperidone palmitate treatment group were injection site pain (18.6% of subjects), insomnia (16.8%), weight increased (11.9%), akathisia (11.1%), and anxiety (10.6%).

CONCLUSIONS:

In a trial designed to reflect real-world management of schizophrenia, once-monthly paliperidone palmitate demonstrated superiority compared to oral antipsychotics in delaying time to treatment failure.

TRIAL REGISTRATION:

Clinicaltrials.gov Identifier: NCT01157351.

© Copyright 2015 Physicians Postgraduate Press, Inc.

Background to the Neuroscience-based nomenclature

PROF Ole Andreassen | V1 -HD 1080p

E-Alert

Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre

search this site

Search form

New levels of schizophrenia care through optimal delivery of treatment

Available to download for your personal use - Professor Emsley presents a selection of slides from ‘Empowering the Healthcare community: Reaching new levels in schizophrenia care’ as developed by the PsyAcademy Continuous Treatment Expert Committee.

 

View the video

Therapeutic actions of antipsychotics

Download lectures and guides on antipsychotics by Dr. Stephen M. Stahl:

View the video

Share